Related Experiment Video

Updated: May 26, 2026

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

Alcohol dosing and the heart: updating clinical evidence

Matteo Nicola Dario Di Minno1, Massimo Franchini, Anna Russolillo

  • 1Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy. dario.diminno@hotmail.it

Seminars in Thrombosis and Hemostasis
|December 27, 2011
PubMed

Insights

Light to moderate alcohol consumption may offer cardiovascular protection, but safe limits vary by sex and age. Regular wine consumption with meals is linked to better heart health outcomes than binge drinking.

Area of Science:

  • Cardiovascular Medicine
  • Public Health
  • Nutritional Science

Background:

  • Heavy or irregular alcohol consumption is known to have negative health consequences.
  • Emerging evidence suggests light to moderate alcohol intake may protect against vascular and all-cause mortality, ischemic stroke, peripheral arterial disease, and congestive heart failure.

Purpose of the Study:

  • To review current information on alcohol consumption and cardiovascular health.
  • To delineate safe drinking limits and patterns for healthy individuals and patients with cardiovascular disease.
  • To explore the potential benefits of different types of alcoholic beverages, particularly wine.

Main Methods:

  • Literature review and synthesis of existing research on alcohol consumption and cardiovascular pathophysiology.
  • Analysis of potential confounders and underlying mechanisms related to alcohol's effects.
  • Evaluation of recommended safe drinking guidelines and beverage preferences.

Main Results:

  • Recommended safe limits: up to 2 standard drinks/day for men, 1 drink/day for non-pregnant women. Young premenopausal women may have an unfavorable risk-benefit balance.
  • Patients with cardiovascular disease should not exceed 1-2 drinks/day for women, 2-3 drinks/day for men.
  • Regular, daily consumption (e.g., wine with meals) is associated with better outcomes than binge drinking. Wine shows higher anti-inflammatory effects than spirits.

Conclusions:

  • Light to moderate alcohol consumption, particularly wine with meals, may offer cardiovascular benefits within recommended limits.
  • Individualized risk-benefit assessments are crucial, especially for women and those with pre-existing cardiovascular conditions.
  • Wine consumption is generally preferred over liquor or beer due to its anti-inflammatory properties.

More Related Videos

The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans05:40

The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans

Published on: April 28, 2022

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

Related Concept Videos

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...